Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
US |
|
Pexip Holding ASA
OSE:PEXIP
|
NO |
|
H
|
Harn Len Corporation Bhd
KLSE:HARNLEN
|
MY |
|
CVB Financial Corp
NASDAQ:CVBF
|
US |
|
Nephros Inc
NASDAQ:NEPH
|
US |
|
Atlantic Navigation Holdings (Singapore) Ltd
SGX:5UL
|
SG |
|
L
|
Lion Energy Ltd
ASX:LIO
|
AU |
|
Hitech Group Australia Ltd
ASX:HIT
|
AU |
|
B
|
BHI Co Ltd
KOSDAQ:083650
|
KR |
|
EHang Holdings Ltd
NASDAQ:EH
|
CN |
|
D
|
Daphne International Holdings Ltd
HKEX:210
|
CN |
|
CNMC Goldmine Holdings Ltd
SGX:5TP
|
SG |
|
Equitable Group Inc
TSX:EQB
|
CA |
Wall Street
Price Targets
CPRX Price Targets Summary
Catalyst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
CPRX
is 35.02 USD
with a low forecast of 32.32 USD and a high forecast of 37.8 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CPRX's stock price target?
Price Target
35.02
USD
According to Wall Street analysts, the average 1-year price target for
CPRX
is 35.02 USD
with a low forecast of 32.32 USD and a high forecast of 37.8 USD.
What is Catalyst Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
9%
The
compound annual growth rate
of Catalyst Pharmaceuticals Inc's revenue for the next 3 years is
9%.
What is Catalyst Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
12%
The
compound annual growth rate
of Catalyst Pharmaceuticals Inc's operating income for the next 3 years is
12%.
What is Catalyst Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
6%
The
compound annual growth rate
of Catalyst Pharmaceuticals Inc's net income for the next 3 years is
6%.
